Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAP-001 in Refractory Gout
NCT05690204Phase 2Active, not recruiting
- Sponsor
- Shanton Pharma
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of sap-001 in gout and hyperuricemia (4 arms), sponsored by Shanton Pharma. Primary endpoint: Reduction in serum uric acid levels at 24 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
sap-001
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT05690204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690204.